Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.
A new analysis raises concerns over the stoppage of funding for this long-standing program, which could have major impacts on global public health for years to come.